CL2011002370A1 - Procedimiento de preparacion de un inhibidor de citrocromo p450 monoxigenasa y los compuestos intermediarios considerados. - Google Patents

Procedimiento de preparacion de un inhibidor de citrocromo p450 monoxigenasa y los compuestos intermediarios considerados.

Info

Publication number
CL2011002370A1
CL2011002370A1 CL2011002370A CL2011002370A CL2011002370A1 CL 2011002370 A1 CL2011002370 A1 CL 2011002370A1 CL 2011002370 A CL2011002370 A CL 2011002370A CL 2011002370 A CL2011002370 A CL 2011002370A CL 2011002370 A1 CL2011002370 A1 CL 2011002370A1
Authority
CL
Chile
Prior art keywords
intermediates
citrochrome
monoxygenase
inhibitor
preparing
Prior art date
Application number
CL2011002370A
Other languages
English (en)
Spanish (es)
Inventor
Richard Polniaszek
Steven Yu Richard Cullen Aaron Dowdy Eric Pfeiffer
Duong Kent Kenneth Zhou Zhongxin Cor Tran
Original Assignee
Gilead Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42634770&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2011002370(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Gilead Sciences Inc filed Critical Gilead Sciences Inc
Publication of CL2011002370A1 publication Critical patent/CL2011002370A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D277/00Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D277/30Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D277/00Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D277/28Radicals substituted by nitrogen atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C209/00Preparation of compounds containing amino groups bound to a carbon skeleton
    • C07C209/62Preparation of compounds containing amino groups bound to a carbon skeleton by cleaving carbon-to-nitrogen, sulfur-to-nitrogen, or phosphorus-to-nitrogen bonds, e.g. hydrolysis of amides, N-dealkylation of amines or quaternary ammonium compounds
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C209/00Preparation of compounds containing amino groups bound to a carbon skeleton
    • C07C209/68Preparation of compounds containing amino groups bound to a carbon skeleton from amines, by reactions not involving amino groups, e.g. reduction of unsaturated amines, aromatisation, or substitution of the carbon skeleton
    • C07C209/70Preparation of compounds containing amino groups bound to a carbon skeleton from amines, by reactions not involving amino groups, e.g. reduction of unsaturated amines, aromatisation, or substitution of the carbon skeleton by reduction of unsaturated amines
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C303/00Preparation of esters or amides of sulfuric acids; Preparation of sulfonic acids or of their esters, halides, anhydrides or amides
    • C07C303/34Preparation of esters or amides of sulfuric acids; Preparation of sulfonic acids or of their esters, halides, anhydrides or amides of amides of sulfuric acids
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C307/00Amides of sulfuric acids, i.e. compounds having singly-bound oxygen atoms of sulfate groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C307/02Monoamides of sulfuric acids or esters thereof, e.g. sulfamic acids
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C307/00Amides of sulfuric acids, i.e. compounds having singly-bound oxygen atoms of sulfate groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C307/04Diamides of sulfuric acids
    • C07C307/06Diamides of sulfuric acids having nitrogen atoms of the sulfamide groups bound to acyclic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02PCLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00Technologies relating to chemical industry
    • Y02P20/50Improvements relating to the production of bulk chemicals
    • Y02P20/55Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CL2011002370A 2009-04-03 2011-09-26 Procedimiento de preparacion de un inhibidor de citrocromo p450 monoxigenasa y los compuestos intermediarios considerados. CL2011002370A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US16649809P 2009-04-03 2009-04-03

Publications (1)

Publication Number Publication Date
CL2011002370A1 true CL2011002370A1 (es) 2012-05-25

Family

ID=42634770

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2011002370A CL2011002370A1 (es) 2009-04-03 2011-09-26 Procedimiento de preparacion de un inhibidor de citrocromo p450 monoxigenasa y los compuestos intermediarios considerados.

Country Status (27)

Country Link
US (4) US8497396B2 (enExample)
EP (2) EP3009434A1 (enExample)
JP (8) JP5612662B2 (enExample)
KR (3) KR101728375B1 (enExample)
CN (4) CN111217808A (enExample)
AP (1) AP2887A (enExample)
AR (1) AR076027A1 (enExample)
AU (1) AU2010232559B2 (enExample)
BR (1) BRPI1012638B8 (enExample)
CA (4) CA3008903C (enExample)
CL (1) CL2011002370A1 (enExample)
CO (1) CO6400216A2 (enExample)
EA (2) EA201590979A1 (enExample)
EC (1) ECSP11011391A (enExample)
ES (1) ES2548252T3 (enExample)
HK (1) HK1223912A1 (enExample)
IL (4) IL215399A (enExample)
MX (2) MX2011010397A (enExample)
NZ (4) NZ617773A (enExample)
PE (1) PE20120617A1 (enExample)
PT (1) PT2414325E (enExample)
SG (2) SG10201404926UA (enExample)
TW (2) TW201518283A (enExample)
UA (1) UA108738C2 (enExample)
UY (1) UY32535A (enExample)
WO (1) WO2010115000A2 (enExample)
ZA (1) ZA201107430B (enExample)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA108738C2 (uk) 2009-04-03 2015-06-10 Спосіб одержання інгібітора цитохром р450 монооксигенази та залучені проміжні сполуки
JP2012140390A (ja) * 2011-01-06 2012-07-26 Sumitomo Chemical Co Ltd α−アミノ−γ−ブチロラクトンの製造方法
CA2836768A1 (en) * 2011-05-02 2012-11-08 Gilead Sciences, Inc. Amorphous solid salts
SG11201404527QA (en) * 2012-02-03 2014-08-28 Gilead Sciences Inc Methods and intermediates for preparing pharmaceutical agents
WO2014047849A1 (zh) * 2012-09-27 2014-04-03 上海迪赛诺化学制药有限公司 细胞色素p450单加氧酶抑制剂中间体及其制法和用途
CN103694196A (zh) * 2012-09-27 2014-04-02 上海迪赛诺化学制药有限公司 细胞色素p450单加氧酶抑制剂中间体及其制法和用途
WO2014057498A2 (en) 2012-10-08 2014-04-17 Mylan Laboratories Ltd. Process for the preparation of cobicistat intermediates
WO2014105777A1 (en) * 2012-12-26 2014-07-03 Assia Chemical Industries Ltd. Cobicostat dichlohydrate salt
CN104370777A (zh) * 2013-08-13 2015-02-25 上海迪赛诺化学制药有限公司 合成(2r,5r)-1,6-二苯基己烷-2,5-二胺及其盐的中间体及所述中间体的制备方法和应用
US20170035911A1 (en) * 2013-11-29 2017-02-09 Mylan Laboratories Ltd. Amorphous Cobicistat Solid Dispersion
EP3077373B1 (en) 2013-12-03 2018-09-12 Mylan Laboratories Ltd. Preparation of cobicistat intermediates
CN104193643B (zh) * 2014-09-12 2016-02-10 宁波九胜创新医药科技有限公司 用于合成抗艾滋病药物增强剂cobicistat的中间体
CN104447472A (zh) * 2014-11-06 2015-03-25 江苏森萱医药化工股份有限公司 D)-2-苄基-n,n-二甲基氮杂环丙烷基-1-磺酰胺合成方法
CN104557565B (zh) * 2015-01-08 2016-07-06 浙江工业大学 抗艾滋病药物增强剂Cobicistat关键中间体盐酸盐的制备方法
US10454867B2 (en) * 2015-02-09 2019-10-22 Airwatch Llc Enhanced e-mail delivery to mobile devices
WO2016132378A2 (en) * 2015-02-18 2016-08-25 Msn Laboratories Private Limited Novel process for the preparation of 1,3-thiazol-5-ylmethyl [(2r,5r)-5-{[(2s)-2- [(methyl{[2-(propan-2-yl)- 1,3-thiazol-4-yl] methyl} carbamoyl) amino] -4-(morpholin-4-yl)butanoyl]amino}-1,6-diphenylhexan-2-yl] carbamate
CN107674039A (zh) * 2016-08-01 2018-02-09 上海朴颐化学科技有限公司 一种可比西他中间体的制备方法
US20180085387A1 (en) 2016-09-27 2018-03-29 Gilead Sciences, Inc. Therapeutic compositions for treatment of human immunodeficiency virus
CN109912530A (zh) * 2017-12-13 2019-06-21 上海奥博生物医药技术有限公司 一种可比司他原料杂质的制备方法
CN109232301B (zh) * 2018-10-15 2021-01-01 天津希恩思生化科技有限公司 一种四异丙基肼的制备方法
CN110642721B (zh) * 2018-12-21 2022-09-30 安徽贝克生物制药有限公司 盐酸司来吉兰的制备方法
CN110878071A (zh) * 2019-11-21 2020-03-13 华南农业大学 一种α-氨基-γ-丁内酯及其盐的制备方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2324549T5 (es) * 1999-06-04 2012-10-31 Abbott Laboratories Solución farmacéutica que comprende ritonavir, un disolvente (ácido graso de cadena larga) y agua
US20030153771A1 (en) 2001-09-27 2003-08-14 Kolb Hartmuth C. Large scale synthesis of optically pure aziridines
WO2003106445A1 (en) * 2002-06-12 2003-12-24 Qsi Pharma A/S Compounds and methods for controlling bacterial virulence
JP2008507611A (ja) * 2004-07-23 2008-03-13 ザ プロクター アンド ギャンブル カンパニー 油及びデンプン汚れに対する低温での洗浄力を向上させる液体洗剤組成物
US7786153B2 (en) * 2005-03-02 2010-08-31 Abbott Laboratories Inc. Compounds that are useful for improving pharmacokinetics
AP2985A (en) * 2006-07-07 2014-09-30 Gilead Sciences Inc Modulators of pharmacokinetic properties of therapeutics
LT2487163T (lt) * 2007-02-23 2016-10-25 Gilead Sciences, Inc. Terapinių agentų farmakokinetinių savybių moduliatoriai
CA2692331A1 (en) * 2007-07-06 2009-01-15 Gilead Sciences, Inc. Modulators of pharmacokinetic properties of therapeutics
ES2555209T3 (es) * 2008-01-04 2015-12-29 Gilead Sciences, Inc. Inhibidores del citocromo P450
BRPI0911871A8 (pt) 2008-05-02 2018-03-06 Gilead Sciences Inc uso de partículas veículo sólidas para melhorar a processabilidade de um agente farmacêutico
UA108738C2 (uk) 2009-04-03 2015-06-10 Спосіб одержання інгібітора цитохром р450 монооксигенази та залучені проміжні сполуки

Also Published As

Publication number Publication date
JP5986599B2 (ja) 2016-09-06
CA2754698C (en) 2016-06-07
ECSP11011391A (es) 2012-03-30
US9428473B2 (en) 2016-08-30
JP2018162274A (ja) 2018-10-18
KR101874557B1 (ko) 2018-07-04
CA2925137A1 (en) 2010-10-07
PE20120617A1 (es) 2012-05-26
CA3008903C (en) 2021-06-08
SG10201404926UA (en) 2015-02-27
CA3008903A1 (en) 2010-10-07
EA201590979A1 (ru) 2016-02-29
CN102438982A (zh) 2012-05-02
CA3083433C (en) 2022-08-09
EA201190179A1 (ru) 2013-01-30
AP2887A (en) 2014-05-31
MX338731B (es) 2016-04-28
BRPI1012638B8 (pt) 2021-05-25
KR101728375B1 (ko) 2017-04-19
AP2011005864A0 (en) 2011-10-31
NZ726536A (en) 2018-04-27
US8853210B2 (en) 2014-10-07
AR076027A1 (es) 2011-05-11
PT2414325E (pt) 2015-10-29
CN102438982B (zh) 2015-05-06
IL237643A0 (en) 2015-04-30
JP6336161B2 (ja) 2018-06-06
US20160002186A1 (en) 2016-01-07
EP2414325B1 (en) 2015-08-26
HK1245785A1 (zh) 2018-08-31
TW201518283A (zh) 2015-05-16
IL237643A (en) 2017-01-31
CA2925137C (en) 2018-07-31
CN104876888A (zh) 2015-09-02
EA022739B1 (ru) 2016-02-29
SG174585A1 (en) 2011-10-28
NZ594864A (en) 2014-03-28
IL250068A0 (en) 2017-03-30
CA3083433A1 (en) 2010-10-07
IL215399A (en) 2015-11-30
JP2018008983A (ja) 2018-01-18
BRPI1012638A2 (pt) 2016-04-05
CN104876888B (zh) 2018-06-15
JP6180561B2 (ja) 2017-08-16
US20150005493A1 (en) 2015-01-01
NZ708978A (en) 2017-01-27
IL215399A0 (en) 2011-12-29
IL237642A0 (en) 2015-04-30
AU2010232559A8 (en) 2011-11-10
HK1166976A1 (zh) 2012-11-16
AU2010232559A1 (en) 2011-10-06
MX2011010397A (es) 2011-10-24
WO2010115000A2 (en) 2010-10-07
JP5612662B2 (ja) 2014-10-22
KR20180077324A (ko) 2018-07-06
NZ617773A (en) 2016-02-26
UA108738C2 (uk) 2015-06-10
CN111217808A (zh) 2020-06-02
JP2020189861A (ja) 2020-11-26
TWI464165B (zh) 2014-12-11
JP2014193897A (ja) 2014-10-09
JP2012522797A (ja) 2012-09-27
JP6491706B2 (ja) 2019-03-27
TW201100412A (en) 2011-01-01
CN107382997B (zh) 2021-02-26
IL237642A (en) 2017-01-31
JP2017122107A (ja) 2017-07-13
CO6400216A2 (es) 2012-03-15
EP2414325A2 (en) 2012-02-08
CN107382997A (zh) 2017-11-24
JP2016128476A (ja) 2016-07-14
ES2548252T3 (es) 2015-10-15
KR20170043672A (ko) 2017-04-21
HK1214265A1 (zh) 2016-07-22
US8497396B2 (en) 2013-07-30
US20140088304A1 (en) 2014-03-27
UY32535A (es) 2010-10-29
BRPI1012638B1 (pt) 2021-04-20
US20100256366A1 (en) 2010-10-07
HK1223912A1 (en) 2017-08-11
WO2010115000A3 (en) 2011-09-22
AU2010232559B2 (en) 2015-06-18
CA2754698A1 (en) 2010-10-07
ZA201107430B (en) 2012-12-27
EP3009434A1 (en) 2016-04-20
JP2023002679A (ja) 2023-01-10
KR20120006035A (ko) 2012-01-17
US9115100B2 (en) 2015-08-25

Similar Documents

Publication Publication Date Title
CL2011002370A1 (es) Procedimiento de preparacion de un inhibidor de citrocromo p450 monoxigenasa y los compuestos intermediarios considerados.
ECSP12011581A (es) Inhibidores de bace
CR11776A (es) Inhibidores de bace
DOP2014000033A (es) Aminoquinazolinas como inhibidores de quinasa
CR20120334A (es) Derivados de imidazopiridina como inhibidores de jak
MX341456B (es) Amino-quinolinas como inhibidores de cinasa.
CR20120130A (es) Compuestos de benzoxepina inhibidores de la pi3k y métodos de uso
CR20120635A (es) Compuestos heterocìclicos de nitrògeno ùtiles como inhibidores de pde10
UY32640A (es) Aril-pirimidinas como inhibidoras de sintasa dfe aldosterona
UY32049A (es) Inhibidores de cmet
UY34300A (es) COMPUESTOS Y COMPOSICIONES COMO INHIBIDORES DE LA QUINASA c-Kit
MX385616B (es) Inhibidores de cdk
UA104438C2 (uk) Спосіб одержання дабігатрану і його проміжних сполук
CL2012000278A1 (es) Proceso para la obtencion de derivados de 5-trifluorometil-pirimidinas; y uno de los compuestos intermediarios considerados.
MX2012006805A (es) Indolil-piperidinil bencilaminas como inhibidores de beta-triptasa.
DK2483271T3 (da) Pyrazolindionderivater som NADPH-oxidaseinhibitorer
EA201270280A1 (ru) Соединения пиримидина в качестве ингибиторов при лечении туберкулеза
MY169734A (en) Methods for improving pharmacokinetics
PH12013500554A1 (en) Process for preparing pan-cdk inhibitors of the formula (i) and intermediates in the preparation
CL2008003095A1 (es) Procedeimiento de preparacion de dihidrotienopirimidas; uno de los compuestos intermediarios considerados; y el procedimiento de preparacion de dicho compuesto intermediario.
JO3063B1 (ar) مركب مبتكر وطرق لانتاجه
UA107671C2 (en) N1-substityted-5-fluoro-2-oxopyrimidinone-1(2h)-carboxamide derivatives
TN2013000354A1 (en) Synthesis of 2-carboxamide cycloamino urea derivatives
UY32499A (es) Nuevo procedimiento de síntesis de la ivabradina y de sus sales de adición a un ácido farmacéuticamente aceptable
UY32524A (es) Moduladores de sip y método para producirlos y usarlos